Targeting Semaphorin 3C in Castrate Resistant Prostate Cancer

Prostate cancer is the most common malignancy in men and a major cause of cancer deaths. Androgen deprivation therapy (ADT) is the first-line therapy for metastatic prostate cancer but invariable the cancer regrows despite the androgen deprivation – this regrowth is termed castrate resistant prostate cancer. We have discovered that expression of a specific gene (Semaphorin 3C) is associated with the emergence of castrate resistant prostate cancer. The Ong laboratory has developed an inhibitor to the Semaphorin 3C pathway, and the purpose of the current study is to determine what genetic alterations in the tumour cells can result in the emergence of resistance to inhibition of Semophorin 3C signaling.

Shahram Khosravi
Faculty Supervisor: 
Christopher J Ong
British Columbia
Partner University: